NSE/LAURUSLABS

LAURUSLABSLaurus Labs Ltd

Healthcare · NSE

₹1,135.75+0.66%

52-wk low52-WEEK RANGE52-wk high

₹564.25+101.3% from low ·0.0% from high₹1,135.75

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

LAURUSLABS+101.28% · 1Y

Range high ₹1,142.35Range low ₹551Latest ₹1,135.75252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareLargecap

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite17/100

Performance

—

Not enough price history to score.

Valuation

High

Looks expensive vs the sector.

· P/E 73.1 — 93% above sector median 37.8
· P/B 12.79 above sector median

Growth

Medium

Steady but not standout growth.

· Revenue YoY +10.2%
· Profit YoY +123.2% — strong earnings growth

Profitability

Low

Profitability is a concern.

· Net margin 6.5% — thin margins

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(66/100)

Durability

A+

92/100

Financially resilient — strong quality + solvency profile.

Show 3 drivers

Piotroski F-score7/8 (88pt)
Altman Z" score3.69 (100pt)
Debt/Equity0.45 (89pt)

Valuation

14/100

Richly valued on most axes; limited margin of safety.

Show 4 drivers

P/E vs sector (73.1 / 37.8)193% (21pt)
P/B12.79 (16pt)
Dividend yield0.14% (4pt)
EV/EBITDA38.3 (3pt)

Momentum

A+

93/100

Strong, confirmed momentum across price + technicals.

Show 4 drivers

DMA-trend alignmentstrong up (100pt)
RSI (14)68.3 (87pt)
Price vs 200-DMA+18.9% (98pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)73.12

OVERVALUED

CheapestP/E 73.1 at 96th %ile — pricier than 96% of peers.Most expensive

P/B12.79

OVERVALUED

CheapestP/B 12.79 at 100th %ile of sector.Most expensive

EV/EBITDA38.30

OVERVALUED

Monthly seasonality

Avg monthly return over 9 years · historical — not a forecast

Best: Jul +11.53% · Worst: Jan -3.72%

Jan

-3.7%

10% win

Feb

+1.1%

60% win

Mar

+0.5%

50% win

Apr

+11.1%

70% win

May

+0.3%

44% win

Jun

+6.0%

Monthly return distribution

Distribution of 112 monthly returns

Mean

+3.01%

Median

-0.52%

Std dev

13.55%

Best

+79.7%

Worst

-21.5%

% positive

49%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 2

Financial quality score 7/8
Piotroski ≥7 historically associated with outperformance
Bankruptcy risk low (Altman Z″ 3.69)
Z″ above 2.60 sits squarely in the 'safe' zone

WEAKNESSES · 1

Premium to sector on P/E (+93%)
P/E 73.1 vs Healthcare median 37.8

OPPORTUNITIES · 1

Strong uptrend — DMA stack bullish
Price > 20-DMA > 50-DMA > 200-DMA: momentum tailwind intact

THREATS · 1

Valuation compression risk
P/E 73.1 is 93% above sector — any growth miss gets punished

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+0.7%

+3.4%

+13.2%

+3.2%

+30.2%

+96.1%

+53.3%

+26.2%

10Y

+30.3%

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
LAURUSLABSTHIS Laurus Labs Limited	₹1,135.75	+77.4%	61,437	73.1	12.79	—	0.45	+10.2%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%

ASK AXEL

Dig deeper into LAURUSLABS

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for LAURUSLABS — all in one sourced reply.

Ask free in chat

Run these tools on LAURUSLABS

Historical return →

"If I had bought LAURUSLABS in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on LAURUSLABS

Brokerage + charges →

All-in cost for trading LAURUSLABS

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	3.68	4.65	+26.4%
-2q	2.57	3.61	+40.6%
-3q	2.07	3.02	+45.9%
-4q	3.64	4.33	+19.0%

Date	Amount
2025-10-31	₹0.80
2025-05-09	₹0.80
2024-11-06	₹0.40
2024-05-08	₹0.40
2023-11-02	₹0.40
2023-05-10	₹1.20
2022-11-03	₹0.80
2022-05-10	₹1.20
2021-11-17	₹0.80
2021-05-11	₹0.80
2021-02-08	₹0.40
2020-11-10	₹0.80
2020-07-01	₹0.20
2020-03-23	₹0.30
2019-07-03	₹0.30
2018-06-28	₹0.30
2017-07-06	₹0.30

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.100	×6.56	0.656
Retained Earnings / Total Assets (B)	0.377	×3.26	1.228
EBIT / Total Assets (C)	0.168	×6.72	1.131
Book Equity / Total Liabilities (D)	0.645	×1.05	0.677

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q4
Revenue	1,224	1,415	1,674	1,570	1,778
Operating profit	71	179	310	265	360
OPM %	5.8%	12.7%	18.5%	16.9%	20.2%
Interest	53	58	47	52	39
PBT	23	131	312	224	327
Tax %	22.3%	30.7%	25.1%	28.2%	22.5%
Net profit	20	92	234	163	252
EPS (₹)	0.37	1.71	—	3.02	4.65

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	4,889	6,014	5,002	5,508
Operating profit	1,173	1,294	395	625
OPM %	24.0%	21.5%	7.9%	11.3%
Interest	76	123	172	207
Depreciation	251	324	385	430
PBT	1,084	1,109	236	484
Tax %	23.2%	28.2%	28.8%	26.8%
Net profit	828	790	161	358
EPS (₹)	15.35	14.64	2.97	6.64

LAURUSLABSLaurus Labs Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Peer comparison · Healthcare

Ask Axel about LAURUSLABS

Recent news

Dig deeper into LAURUSLABS

Run these tools on LAURUSLABS

Technical snapshot

Earnings history + surprises

Dividends + splits history

Stock scorecard

SWOT analysis

Recent news

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	107	108	108	108
Reserves	2,625	3,302	3,315	3,626
Borrowings	1,777	2,015	2,577	2,764
Other liabilities	67	126	106	348

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	911	994	666	602
CF Investing	-914	-996	-822	-682
CF Financing	30	-27	250	39
Net cash flow	27	-30	93	-39

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	11.3%	7.9%	21.5%	24.0%
Net margin %	6.5%	3.2%	13.1%	16.9%
ROE %	10.0%	4.7%	25.7%	30.3%
ROCE %	11.1%	7.1%	24.8%	25.7%
Debt / Equity	0.74	0.75	0.59	0.65
Interest coverage	3.3×	2.4×	10.0×	15.3×
Revenue growth YoY	+10.1%	-16.8%	+23.0%	—
Profit growth YoY	+123.2%	-79.7%	-4.5%	—